Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBT (2019 - 2025)

Pulmonx (LUNG) has disclosed EBT for 7 consecutive years, with -$13.8 million as the latest value for Q3 2025.

  • Quarterly EBT rose 0.88% to -$13.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$56.3 million through Sep 2025, changed 0.22% year-over-year, with the annual reading at -$55.9 million for FY2024, 7.26% up from the prior year.
  • EBT for Q3 2025 was -$13.8 million at Pulmonx, up from -$15.0 million in the prior quarter.
  • The five-year high for EBT was -$10.1 million in Q3 2021, with the low at -$16.1 million in Q2 2023.
  • Average EBT over 5 years is -$14.0 million, with a median of -$14.0 million recorded in 2022.
  • The sharpest move saw EBT plummeted 165.99% in 2021, then grew 13.81% in 2024.
  • Over 5 years, EBT stood at -$12.9 million in 2021, then fell by 9.2% to -$14.0 million in 2022, then increased by 2.83% to -$13.6 million in 2023, then rose by 3.69% to -$13.1 million in 2024, then dropped by 5.27% to -$13.8 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$13.8 million, -$15.0 million, and -$14.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.